Unibest

Pharmaceutical intermediates

Abrocitinib Intermediates

4 pharmaceutical intermediates for Abrocitinib. Indication: Atopic Dermatitis.

提交项目All intermediates

About Abrocitinib

Originator
Pfizer Inc
Indication
Atopic Dermatitis
Approved Date
01/14/2022
NCE Patent
01/14/2027
DS/DP
02/19/2031

Available intermediates

4 intermediates currently listed for Abrocitinib. Request specifications, documentation or a quotation for any item below.

Abrocitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
benzyl ((1s,3s)-3-(methylamino)cyclobutyl)carbamate1353501-22-0//
Carbamic acid, N-[cis-3-(methylamino)cyclobutyl]-, phenylmethyl ester, hydrochloride (1:1)2204290-99-1//
3-Oxocyclobutane-1-carboxylicacid23761-23-1//
Benzyl 3-oxocyclobutylcarbamate130369-36-7//

Other programs under A

AbemaciclibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidolAlogliptin/ Trelagliptin

Building toward Abrocitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →